Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8 USD | 0.00% | 0.00% | +433.33% |
Sales 2024 * | 22.15M 27.72M 2.22B | Sales 2025 * | 36.37M 45.51M 3.64B | Capitalization | 809M 1.01B 80.86B |
---|---|---|---|---|---|
Net income 2024 * | -42M -52.56M -4.2B | Net income 2025 * | -72M -90.11M -7.2B | EV / Sales 2024 * | 32.4 x |
Net cash position 2024 * | 91.29M 114M 9.13B | Net cash position 2025 * | 82.95M 104M 8.29B | EV / Sales 2025 * | 20 x |
P/E ratio 2024 * |
-46.2
x | P/E ratio 2025 * |
-33.2
x | Employees | 109 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Silence Therapeutics plc
Current month | +6.67% | ||
1 month | +6.67% | ||
3 months | +433.33% | ||
6 months | +1,030.10% | ||
Current year | +433.33% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Tooman
CEO | Chief Executive Officer | 58 | 05/01/21 |
Director of Finance/CFO | 52 | 31/03/21 | |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Romano
CTO | Chief Tech/Sci/R&D Officer | 64 | 28/07/19 |
David Lemus
BRD | Director/Board Member | 61 | 20/06/18 |
Iain Ross
CHM | Chairman | 71 | 01/07/04 |
EPS Revisions
- Stock Market
- Equities
- SLN Stock
- SLNCF Stock